Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding

Start-Up Has Two Clinical-Stage Product Candidates

Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations. 

Finance Watch Private Company
• Source: Shutterstock

Morningside Ventures launched Adiso Therapeutics on 10 March with more than $60m invested to date in the Concord, MA-based start-up focusing on the underlying biology of inflammatory diseases without causing systemic immunosuppression. Adiso has two assets in clinical development for the prevention of C. difficile infection recurrence and treatment of ulcerative colitis as well as a discovery-stage effort in respiratory inflammation under way.

The company’s efforts have been funded entirely by Morningside to date and the investment firm intends to support Adiso’s growth...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.